Protocol 2017.008.01: Efficacy and safety of AbGn-168H in patients with moderate to severe active, anti-TNF 􀁄 and/or anti-integrin refractory ulcerative colitis: a 26-week, open-label, multi-center, hase II proof of principle trial

Project: Research project

Project Details

StatusFinished
Effective start/end date1/29/19 → 1/29/22

Funding

  • Parexel (Protocol 2017.008.01 // Protocol 2017.008.01)
  • AbGenomics International Inc. (Protocol 2017.008.01 // Protocol 2017.008.01)